Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Lakshmi Sriharsha"'
Autor:
Jeffrey H. Lipton, Hans A. Messner, Katherine Siminovitch, Xiangdong Liu, Suzanne Kamel-Reid, Wei Xu, Lakshmi Sriharsha, Dong Hwan (Dennis) Kim
Purpose: Imatinib resistance is major cause of imatinib mesylate (IM) treatment failure in chronic myeloid leukemia (CML) patients. Several cellular and genetic mechanisms of imatinib resistance have been proposed, including amplification and overexp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3b6b8a157adb8ebebb8cc641d697f2
https://doi.org/10.1158/1078-0432.c.6517617
https://doi.org/10.1158/1078-0432.c.6517617
Autor:
Jeffrey H. Lipton, Hans A. Messner, Katherine Siminovitch, Xiangdong Liu, Suzanne Kamel-Reid, Wei Xu, Lakshmi Sriharsha, Dong Hwan (Dennis) Kim
Supplementary Data from Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::757decf5518ce3e5ec1bb390d9b3cafd
https://doi.org/10.1158/1078-0432.22440264.v1
https://doi.org/10.1158/1078-0432.22440264.v1
Autor:
Suzanne Kamel-Reid, Xiangdong Liu, D.H. Kim, Jeffrey H. Lipton, Wei Xu, Hans A. Messner, Lakshmi Sriharsha, Katherine A. Siminovitch
Publikováno v:
Clinical Cancer Research. 15:4750-4758
Purpose: Imatinib resistance is major cause of imatinib mesylate (IM) treatment failure in chronic myeloid leukemia (CML) patients. Several cellular and genetic mechanisms of imatinib resistance have been proposed, including amplification and overexp
Autor:
Lakshmi Sriharsha, Suzanne Kamel-Reid, Hans A. Messner, Gizelle Popradi, Hong Chang, D.H. Kim, Jeffrey H. Lipton
Publikováno v:
Cancer. 113:772-781
BACKGROUND. Although deletion of the derivative chromosome 9 (der 9; del-der 9) carries a poor prognosis in patients with chronic myeloid leukemia (CML) who are treated with hydroxyurea or interferon, its significance in patients on imatinib mesylate
Autor:
Pierre Laneuville, Hans A. Messner, Gizelle Popradi, Lakshmi Sriharsha, Dong Hwan Kim, Jeffrey H. Lipton
Publikováno v:
Clinical Leukemia. 2:55-63
Background Dasatinib is a potent inhibitor of multiple tyrosine kinases, including Bcr-Abl and Src. Pleural effusions have occurred at an incidence of 21% in phase II studies with dasatinib. We investigated the incidence, clinical course, and managem
Autor:
Jerald P. Radich, Lakshmi Sriharsha, Suzanne Kamel-Reid, Chul Won Jung, D.H. Kim, Jeffrey H. Lipton
Publikováno v:
American journal of hematology. 85(11)
Early recognition of high-risk patient is important to improve long-term outcomes following imatinib therapy for chronic myeloid leukemia (CML). Some controversy surrounds the question, which of short-term response parameters at which time-point, inc
Autor:
Clement Ma, Lakshmi Sriharsha, Hans A. Messner, Jeffrey H. Lipton, Sumit Raybardhan, Jack T Seki, Greg Pond
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 15(4)
Background. There is no consensus on a universal dosing method for calculating high-dose chemotherapy in allogeneic Stem Cell Transplant (SCT) patients. The Metropolitan Life (Met-Life) Insurance Company’s weight—height tables have been used to d
Autor:
Jina Yun, Chul Won Jung, Jeffrey H. Lipton, Lakshmi Sriharsha, Jerald P. Radich, Kihyun Kim, Dong Hwan Kim, Suzanne Kamel-Reid, Jun Ho Jang, Jung A. Kim
Publikováno v:
Blood. 114:1110-1110
Abstract 1110 Poster Board I-132 Introduction Early recognition of high-risk patients is important when planning further therapeutic intervention for imatinib treatment failure in patients with chronic myeloid leukemia (CML). Current guideline such a
Autor:
Hyeoung-Joon Kim, Silvia Park, Jee Hyun Kong, D.H. Kim, Jeffrey H. Lipton, Yeo-Kyeoung Kim, Wei Xu, Lakshmi Sriharsha, Chul Won Jung, Suzanne Kamel-Reid
Publikováno v:
Blood. 114:2178-2178
Abstract 2178 Poster Board II-155 Purpose: Interferon therapy had served as a standard therapy before introduction of imatinib into the treatment of chronic myeloid leukemia (CML) although its action mechanism is yet fully elucidated. After introduct
Autor:
Hong Chang, Lakshmi Sriharsha, Dong Hwan Kim, Jeffrey H. Lipton, Hans A. Messner, Suzanne Kamel-Reid
Publikováno v:
Blood. 110:1950-1950
Background: Deletion of the derivative chromosome 9 (der 9; del-der9) is a poor prognostic factor in chronic myeloid leukemia (CML) patients treated with hydroxyurea or interferon. However, its prognostic implication in imatinib mesylate (IM) treated